Private equity is seeing more succession planning and corporate carve-out opportunities in Japan, but there is a risk that exuberance might turn irrational
Japanese private equity has been gradually bouncing back from the 2006-2007 leveraged buyout boom for a number of years. However, a recent upturn in investment activity and an improvement in LP sentiment...
Even if pan-Asian buyout firms aren't actively pursuing investments in internet-related businesses, they cannot ignore the potential disruptive impact of these technologies on other portfolio companies
Mekong Capital's 6.3x return on its investment in Vietnam-based pharmaceuticals player Traphaco involved turning the company's distribution model on its head, as well as supporting expansion and improving governance
China Renaissance has added dedicated healthcare and mezzanine debt strategies to its existing growth-stage private equity offering as part of efforts to more than treble its assets under management (AUM) over the next three years.
China Venture Capital Fund, a VC vehicle backed by the Chinese government, and ChinaEquity Group have jointly led a RMB670 million ($101 million) round for 3D Medicines, which focuses on personalized diagnostics and treatment for cancer.